Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech binary events -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (147)	3/26/2004 1:19:12 PM
From: Icebrg	Read Replies (1) \| Respond to of 295

I used to hold NPSP, but felt I had to follow managment's example and sell the shares. There has been around 120 Form 4s filed since mid-July of last year. So, no doubt management is hedging a lot. Amgen's AMG162 might perhaps dampen some of the "enthusiasm" surrounding Preos. (See relevant part of from the PR issued earlier this week below). Twice yearly SC injections sounds quite good. If I remember correctly Jackson has said that they will partner if they can avoid the black box as that would make the potential market large enough to make it interesting for a big pharma partner. Erik AMG 162 is Amgen's fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (RANKL), a key mediator of the body's natural pathway of the resorptive phase of bone remodeling. Amgen is the innovator of this biologic response modifier, one which may offer improved therapy for diseases associated with bone loss, like osteoporosis. Intended to be administered twice- yearly through SC injections, AMG 162 has the potential to address key unmet patient and physician needs. Amgen presented interim data from a Phase 2 clinical study demonstrating the clinical effect of AMG 162 on bone endpoints. Based on preliminary clinical data, AMG 162 appears to be well-tolerated. Amgen anticipates the initiation of a Phase 3 clinical study with AMG 162 in osteoporosis in 2004.